2955634-67-8
Chemical Structure
(R)-SKBG-1
- CAS No.: 2955634-67-8
- Formula:C22H26ClN3O6S
- Molecular Weight:495.98
InChIKey: SXQZEMXQTRNLRZ-HXUWFJFHSA-N
SMILES: O=S(N1[C@@H](C(NCC2=CC=C(OC)C=C2)=O)CN(C(CCl)=O)CC1)(C3=CC=C(OC)C=C3)=O
Biological Activity: (R)-SKBG-1 is a covalent inhibitor targeting the RNA binding protein NONO. (R)-SKBG-1 can reduce the expression of androgen receptor (AR) and its splice variants, inhibiting cancer cell proliferation. (R)-SKBG-1 inhibits androgen receptor expression with IC50 of 3.1 μM and 5.5 μM for AR-FL mRNA and AR-V7 mRNA, respectively. (R)-SKBG-1 interferes with the gene regulatory network of cancer cells and inhibits cancer cell growth by stabilizing the interaction between NONO and mRNA. (R)-SKBG-1 can be used in the study of cancers related to NONO dysfunction, such as prostate cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-SKBG-1 | 99.68% | (R)-SKBG-1 is a covalent inhibitor targeting the RNA binding protein NONO. (R)-SKBG-1 can reduce the expression of androgen receptor (AR) and its splice variants, inhibiting cancer cell proliferation. (R)-SKBG-1 inhibits androgen receptor expression with IC50 of 3.1 μM and 5.5 μM for AR-FL mRNA and AR-V7 mRNA, respectively. (R)-SKBG-1 interferes with the gene regulatory network of cancer cells and inhibits cancer cell growth by stabilizing the interaction between NONO and mRNA. (R)-SKBG-1 can be used in the study of cancers related to NONO dysfunction, such as prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kathman SG, et al. Remodeling oncogenic transcriptomes by small molecules targeting NONO. Nat Chem Biol. 2023 Jul;19(7):825-836. [Content Brief]
- [2]. Takeiwa T, et al. Role of RNA binding proteins of the Drosophila behavior and human splicing (DBHS) family in health and cancer. RNA Biol. 2024 Jan;21(1):1-17. [Content Brief]
- [3]. Schmeing S, et al. Challenges in Therapeutically Targeting the RNA-Recognition Motif. Wiley Interdiscip Rev RNA. 2024 Nov-Dec;15(6):e1877. [Content Brief]
